OmniAb
OmniAb, Inc.
OmniAb, Inc. is a biotechnology company that provides the biopharmaceutical industry with an advanced technology platform for the discovery and development of novel, fully human therapeutic antibodies. Spun off from Ligand Pharmaceuticals and becoming a public entity in November 2022, the company licenses its proprietary Biological Intelligence™ (BI) platform to partners. This enables the creation of next-generation therapeutics for a wide range of diseases, including oncology and autoimmune disorders.
Products & Team
Biological Intelligence™ (BI) Platform
The Biological Intelligence™ (BI) platform is OmniAb's core offering, an integrated suite of technologies designed for therapeutic antibody discovery. It leverages the immune systems of various genetically engineered transgenic animals to generate a diverse range of high-quality human antibodies, complemented by in silico computational tools that use AI and machine learning to analyze and predict optimal drug candidates.
The platform addresses key challenges in drug discovery by efficiently generating a high diversity of well-characterized, fully human antibody candidates. This streamlines the development timeline for partners and increases the likelihood of finding effective therapeutics for complex diseases and difficult-to-drug targets.
Customers face significant hurdles in drug discovery, including the time, cost, and technical complexity of identifying high-quality therapeutic antibodies that are safe and effective. OmniAb's platform addresses these issues by providing a streamlined, efficient, and technologically diverse solution that reduces discovery risk and accelerates development timelines.